BridgeBio Pharma’s Pipeline Expansion Continues As Existing Portfolio’s Milestones Approach

BridgeBio Pharma Inc. is poised to achieve its goal of rapidly bringing treatments for genetic diseases and genetically defined cancers to the market with two different products expected to be submitted to the US Food and Drug Administration before the end of 2021 – just four years after the company’s first big funding round.

Palo Alto, CA-based BridgeBio recently raised $463.7m in net proceeds from the sale of 2.5% convertible senior notes due in 2027 with an aggregate principal amount of $475m and could net as much as $537m by the time the debt sale concludes. The proceeds, on top of the $577